Loading
Latest filing published 04 Mar 2022 for Cortexyme, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Michael J. Detke, listed as senior executive, appears in our data through filings on IRulya Therapeutics Inc. shares, published by SEC (Form 4). Over a trading history stretching from 6 July 2021 to 3 March 2022, the count stands at 3 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
On 4 March 2022 came the latest disclosure, a share grant in IRulya Therapeutics Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations